Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure

Drug Des Devel Ther. 2017 Feb 23;11:497-502. doi: 10.2147/DDDT.S130945. eCollection 2017.


Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes. Patients reported improvements in general health, fatigue, and emotional and mental well-being after completing combination therapy. The combination treatment is effective, but does need to be administered with caution in patients receiving certain medications or with certain diseases. Herein, we review the safety and efficacy of sofosbuvir/velpatasvir combination regimen for all HCV genotypes.

Keywords: genotype; hepatitis C; pan-genotypic; sofosbuvir; treatment; velpatasvir.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Carbamates / administration & dosage
  • Carbamates / therapeutic use*
  • Genotype
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Sofosbuvir / administration & dosage
  • Sofosbuvir / therapeutic use*


  • Antiviral Agents
  • Carbamates
  • Heterocyclic Compounds, 4 or More Rings
  • velpatasvir
  • Sofosbuvir